Concomitant CC and E2 Versus CC Alone in Ovulation Induction
NCT ID: NCT02186782
Last Updated: 2017-03-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
600 participants
INTERVENTIONAL
2014-06-30
2018-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Value of Addition of Human Menopausal Gonadotropin Drug Following Oocytes Retrieval in IVF Cycles
NCT03209687
Clomiphene Citrate (CC) Co-treatment With HP Urinary FSH vs HP Urinary FSH in CC-resistant PCOS
NCT01212263
Does Clomiphene Citrate Used for Induction of Ovulation Effect Levels of AMH and Inhibin B
NCT02036411
Effect of Local Endometrial Injury on Pregnancy Outcomes During Ovulation Induction Cycles
NCT02345837
Incremental Clomiphene Citrate Doses in Successive Cycles and FSH, LH and Steroid Hormone Levels
NCT04210765
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Clomiphene citrate-Estradiol group
Women will receive clomiphene citrate and estradiol
Clomiphene citrate and Estradiol
Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and estradiol (2 mg/day for 5 consecutive days from day 2 of cycle)
Clomiphene citrate group
Women will receive clomiphene citrate and placebo
Clomiphene citrate and Placebo
Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and placebo (for 5 consecutive days from day 2 of cycle)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clomiphene citrate and Estradiol
Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and estradiol (2 mg/day for 5 consecutive days from day 2 of cycle)
Clomiphene citrate and Placebo
Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and placebo (for 5 consecutive days from day 2 of cycle)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Unexplained infertility.
Exclusion Criteria
* Body mass index (BMI) \< 18.5 kg/m2 or \> 25 kg/m2.
* Presence of any infertility factor other than anovulation/oligoovulation.
* Previous history of ovarian surgery or surgical removal of one ovary.
* Previous exposure to cytotoxic drugs or pelvic irradiation.
* Metabolic or hormonal abnormalities.
20 Years
39 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Maher elesawi kamel elesawi
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Maher elesawi kamel elesawi
Dr
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahmed M Badawy, Prof
Role: PRINCIPAL_INVESTIGATOR
Mansoura University
Maher E Kamel Elesawi, Dr
Role: STUDY_DIRECTOR
Mansoura University
Mohamed S Abdelhafez, Dr
Role: STUDY_DIRECTOR
Mansoura University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Obstetrics and Gynecology Department in Mansoura University Hospital
Al Mansurah, Dakahlia Governorate, Egypt
Private practice settings
Al Mansurah, Dakahlia Governorate, Egypt
Private practice settings
Mīt Ghamr, Dakahlia Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ME1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.